Optina Diagnostics Inc.

Home
Canada
Montreal, QC
Optina Diagnostics Inc.

At Optina, we are re-imagining the diagnosis of systemic diseases. It is more important than ever to propel research in cognitive decline to a new level.

Our revolutionary approach combines state-of the art eye imagery and artificial intelligence to help healthcare professionals improve disease detection. Our first test for Cerebral Amyloid Status, identifies an important risk factor for Alzheimer’s disease. With this test, Optina aims to shape the future and change mindsets when it comes to Brain Health, by providing easily accessible and meaningf

ul information for physicians evaluating patients with cognitive decline. We all know someone suffering from memory loss, and the uncertainties and worries it provokes for them and their loved ones. With the current diagnostic tools, it is difficult to evaluate the exact clinical condition, even for experts in dementia. At the same time, early detection allows the patient to make lifestyle changes that may delay the disease, or possibly even improve cognition. Come and join us, together we can make memory loss a souvenir. https://optinadx.com/get-involved/

12/07/2023

Alzheimer’s disease is a growing public health concern. Worldwide, at least 55 million people are believed to suffer from Alzheimer’s disease or some other form of dementia. This figure will roughly double every 20 years, reaching 78 million in 2030 and 139 million in 2050.

Alzheimer’s has a profound impact on the lives of those diagnosed and their families. The progressive nature of the disease, leading to cognitive decline, memory loss, and behavioral changes, significantly affects daily life.

Part of the challenge is to diagnose the disease, particularly in its early stages, when symptoms can be quite subtle. Ongoing research and efforts are being made to develop innovative approaches to both diagnose and treat the disease. 🔬

With its Retinal Deep PhenotypeTM platform, Optina is at the forefront of an innovative technology that rethinks the diagnosis of debilitating systemic diseases, with its first application being a key risk indicator for Alzheimer’s disease. 👁️

To learn more about Optina’s research, click here 👉 https://optinadx.com/what-we-do

11/30/2023

Caregivers play a vital role in supporting individuals, including those with Alzheimer's disease. To provide the best care, it's crucial for caregivers to assess needs regularly and access valuable resources. Here are essential resources for Alzheimer's caregivers 👇

Alzheimer's Association: Offers caregiving tips, support groups, and educational materials. https://www.alz.org/help-support/caregiving
Alzheimer's Foundation of America: Provides caregiver support groups and local service information. https://alzfdn.org/caregiving-resources/alzheimers-and-dementia-support-groups/
AARP: Offers legal and financial planning resources for caregivers. https://www.aarp.org/caregiving/
Family Caregiver Alliance: Provides online courses and workshops for caregiving skills. https://www.caregiver.org/
Eldercare Locator: Connects caregivers to local services, including dementia care specialists. https://eldercare.acl.gov/Public/Index.aspx
AgingCare.com: Offers information on caregiving technology and apps. https://www.agingcare.com/
ARCH National Respite Network and Resource Center: Provides information on respite care services and support. https://archrespite.org/

Remember, caregivers should also seek support for themselves. This National Family Caregivers Month, we appreciate and recognize the challenges caregivers of Alzheimer's patients face, and we hope these resources help support their well-being. Thank you for your dedication! 💜

11/23/2023

Happy Thanksgiving! 💜

At Optina, we are very grateful for all the support we have received from our collaborators, investors, scientists and all members of our Optina family who have helped us move our technology forward.

Thanks to all of you, we are one step closer to bringing it to millions of patients in need! May you and your family, especially those who need care and those who provide it to them, have a wonderful Holiday!

11/16/2023

At Optina, we honor all caregivers who play a central role in maintaining the well-being, dignity, and overall quality of life of an Alzheimer’s patient, throughout the course of the disease. 🫂

The need for caregiving in Alzheimer’s patients can vary considerably depending on the stage and severity of the disease, as well as the overall health of the person and their support system.

In the early stages of Alzheimer’s disease, individuals may be able to manage daily activities with minimal assistance. However, as the disease progresses, memory loss, confusion, and behavioral changes worsen and may require more extensive care and supervision.

While some Alzheimer’s patients may receive support from family members, friends, or home health aides, many individuals with advanced Alzheimer’s disease end up needing professional caregiving services, either at home or in a specialized care facility, to ensure their safety and well-being.

In short, duties performed by caregivers for Alzheimer’s patients are crucial to meeting the patients’ physical, emotional, and social needs.

To learn more about Optina’s Retinal Deep PhenotypingTM platform currently in development to help assess underlying causes of dementia, click here 👉 https://optinadx.com/what-we-do

Alzheimer's Association Alzheimer's Disease International

11/09/2023

November is National Caregivers’ month. A time to pay tribute to caregivers and recognize their invaluable contributions to society. Caregivers, including healthcare professionals and family members, play a crucial role in supporting individuals with Alzheimer’s disease, a progressive neurodegenerative disorder that affects a person’s memory, thinking, and behavior. As the disease progresses, people suffering from Alzheimer’s often require increasing levels of assistance with daily activities.

At Optina, we honor and appreciate all caregivers for their dedication, compassion, hard work, and support of their loved ones suffering from Alzheimer’s disease.

To learn more about Optina’s Retinal Deep PhenotypingTM platform currently in development to help assess underlying causes of dementia, click here 👉 https://optinadx.com/what-we-do

Alzheimer's Association Alzheimer's Disease International

11/02/2023

✨In a rapidly evolving medical landscape, it's not enough to be part of the change; we aim to be the catalyst. Alzheimer's detection is on the brink of a transformative era, and we're at the helm.

By melding cutting-edge AI with deep medical insights, we're crafting a blueprint for unparalleled precision in detection. But it's not just about technology—it's about a paradigm shift in understanding, approach, and action. We're not just detecting; we're foreseeing, leading the way in a journey from insights to revelations. Join us as we push boundaries, challenge conventions, and usher in a new dawn for Alzheimer's technology. 🌟

To learn more about Optina’s research, click here 👉 https://optinadx.com/what-we-do

Alzheimer's Association Alzheimer's Disease International

10/26/2023

🚀 Pioneering the Future with Optina Diagnostics: While many are still connecting the dots in Alzheimer's detection, we're crafting a new constellation.

Our retinal scanning technology is more than just advanced; it's transformative. From redefining the visible spectrum of detection to illuminating the intricacies of brain health, we stand unmatched. 🧠

As others navigate the challenges of limited data, we thrive, turning every obstacle into a stepping stone. Dive into a realm where innovation meets precision, where real-world challenges find real-world breakthroughs. 🌐

Join us in our quest to not only predict but reshape the future of Alzheimer's detection. The medical revolution isn't on the horizon; it's unfolding right now with Optina. Investors, visionaries, trailblazers – are you ready to be part of the seismic shift? 💡

Alzheimer's Disease International Alzheimer's Association

10/19/2023

Our Retinal Deep PhenotypingTM platform combines a powerful hyperspectral camera, Optina-4CTM, and AI-driven technology, awAIrTM system, which can identify subtle changes that are invisible to any other current technologies.

We uncover unique, unprecedented, and never-before-detected information by capturing and processing light intensity through the retina. 👁️

Our first indication is for the cerebral amyloid status detection to support the Alzheimer's disease diagnosis. Our goal is to provide specialists and primary care physicians with the necessary tools to answer their patients' most crucial question : ''What is the cause of my memory concerns?''

We are also working on a broad range of different algorithms and detection tests for a multitude of systemic diseases. 🔬

To learn more, click here 👉 https://optinadx.com/what-we-do

09/25/2023

We are thrilled and proud to announce we were selected as a Finalist for The Digital Health Hub Foundation and Digital Health Awards 2023 in the Rising Stars Clinical Diagnostic Device category! 🏆
The Digital Health Awards honor outstanding health technologies and innovations dramatically transforming healthcare. 🩺

This acknowledgment showcases Optina’s strong dedication towards reimagining the diagnosis of debilitating systemic diseases. The Digital Health Awards celebrates and recognizes the finalists for their excellence in utilizing digital advancements to improve healthcare services and patient outcomes. As a finalist, Optina has earned its reputation as a leader in early detection of Alzheimer's Disease signs, employing a 1-sec, patient-friendly retinal scan. 👁️

To learn more about Optina's research, click here 👉https://optinadx.com/what-we-do

09/21/2023

💜 Today on World Alzheimer’s Day, health organizations across the world focus their efforts on raising awareness about Alzheimer’s. This disease hit over 5️⃣0️⃣ million people in 2020, a number that will almost double every 20 years to reach 82 million in 2030 and 1️⃣5️⃣2️⃣ million in 2050.

📉 While deaths due to other major diseases have decreased, deaths from Alzheimer’s disease have increased significantly 📈

At Optina, we aim to support and increase awareness about Alzheimer’s disease by concentrating our efforts on developing our Deep Retinal Phenotype™ platform that will help patients and healthcare providers access early diagnosis and appropriate treatment🔬

To learn more about our research, click here 👉 https://optinadx.com/what-we-do

09/14/2023

Meet Chantal Miklósi, Optina Diagnostics’ Co-founder and CFO.
With nearly three decades in finance, first as an investment banker, then rising to become the CFO of a San Francisco-based and publicly-traded investment bank on the NYSE, she brings a unique blend of corporate wisdom and rigor while cultivating an entrepreneurial spirit. 🏦

At Optina, Chantal plays an essential role in fundraising, ensuring transparency and accurate reporting to stakeholders and the market. Alongside Optina’s co-founders, she balances vision and ex*****on, while navigating a challenging diagnostics landscape.
Together, they’ve successfully raised the necessary capital to bring Optina to its current advanced stage, with an expected product launch by the second half of 2024.🔬

🇨🇦 🇺🇸 Drawing on both American and Canadian approaches to investment and upholding a steadfast commitment to quality and transparency, Chantal is integral to maintaining Optina at the forefront of innovative technology, one careful step at a time.

09/08/2023

September is Alzheimer’s Awareness Month. 💜

Let’s raise awareness and challenge the stigma that persists around Alzheimer’s disease and all types of dementia. 🧠

The burden of Alzheimer’s disease in the United States is growing significantly. 📈

According to the Centers for Disease Control and Prevention, Alzheimer’s is one of the top 10 leading causes of death and ranking 5th among adults aged 65 years or older. In addition, an estimated 15-18% (about 11 to 13 million) of people over 60 suffer from mild cognitive impairment (MCI), with the risk increasing with age. Hence the importance of early diagnosis and discussion with the family physician about the early signs of MCI.

Optina’s team is relentlessly working on its first application, a key risk indicator supporting the diagnosis of Alzheimer’s disease. 🔬

To learn more, click here 👉 https://optinadx.com/

Address

8200 Décarie Boulevard, Suite 220
Montreal, QC
H4P2P5

Telephone

+15143940797

Website

https://optinadx.com/

Alerts

Be the first to know and let us send you an email when Optina Diagnostics Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Optina Diagnostics Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in Montreal?